Familial hypercholesterolaemia: PCSK9 inhibitors are coming (Q85678148)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282517%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Familial hypercholesterolaemia: PCSK9 inhibitors are coming (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282517%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282517%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Raul D Santos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282517%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

1 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282517%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282517%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

385

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282517%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

9965

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282517%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

307-310

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282517%20AND%20SRC:MED&resulttype=core&format=json

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Lipoprotein(a) Levels in Familial Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

PCSK9: a convertase that coordinates LDL catabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Lipid-lowering treatment for homozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

LDL cholesterol: controversies and future therapeutic directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961702-5

7 January 2021

10.1016/S0140-6736(14)61702-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282517%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference